Real-World Endpoints in Stereotactic Body Radiotherapie Trials for Oligoprogression: Beyond Progression-Free Survival and Algehele overleving

Oligoprogressive disease is a clinically distinct scenario, characterized by limited progression (typically 1-5 metastatic sites), during otherwise effective systemic therapy, where the majority of disease sites remain controlled. This can occur in the context of either widespread or limited disease.1 Earlier identification of oligoprogression is becoming more common due to advances in diagnostic and imaging technology. As systemic therapies become more effective and better tolerated, clinicians and their patients are increasingly reluctant to switch treatments based on limited progression, viewing such lesions as potentially treatment-resistant subclones that benefit from locally ablative therapy, until progression becomes more extensive.